{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.80 vs. cons $1.77",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Aflac Japan sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~\u00a521.0B vs. cons \u00a520.5B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Aflac U.S. net earned premium growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~3.5% vs. cons 3.4%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Aflac Japan sales outlook",
      "prediction": "BETTER",
      "answer": "guide ~\u00a580B vs. cons \u00a579B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Aflac Japan benefit ratio",
      "prediction": "UNCHANGED",
      "answer": "guide ~61.5% midpoint vs. cons 61.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Aflac U.S. pretax margin",
      "prediction": "LOWER",
      "answer": "guide ~18.5% midpoint vs. cons 19.2% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.6,
  "day1_confidence": "LOW",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 residual ~+1.6% fades to a five-day cumulative residual of ~+0.4% because the expected EPS and Japan-sales beats support the initial move, but unchanged underwriting ranges and an approximately 18.5% U.S. margin outlook versus 19.2% consensus limit out-period estimate revisions.",
  "day5_confidence": "MEDIUM"
}